3 Smart Money Accounts Invest $15.7 Thousand Believing Hormuz Strait Traffic Will Return to Normal by July
According to monitoring, on the prediction market Polymarket, 3 whales have invested $15.7 thousand in the question "Will traffic in the Strait of Hormuz return to normal before July?", with the current probability of "Yes" at 62.0%.
Out of these 3 whales, 0x8072e357 has a win rate of 62% in the Iran category, with a total profit of $19 thousand; Car has a win rate of 67% in the geopolitics category, with a total profit of $557 thousand; Huludubu has a win rate of 70% in the geopolitics category, with a total profit of $191 thousand.
Today, as Trump orders the U.S. military to take a tougher stance against Iranian boats, he also announces that the mine-clearing operation in the Strait of Hormuz will be "tripled," with the U.S. preparing for future navigation conditions to be restored.
The Strait of Hormuz carries approximately 20% of the global liquid oil consumption flow rate and about 20% of the global LNG supply. Disruptions from the Iran conflict and the Hormuz shipping route are driving up U.S. corporate input and output prices. Supply delays are exacerbating the situation, leading economists to predict accelerated inflation, making it harder for the Fed to cut rates.
Accounts:
0x8072e357dcfed151a7804026b70a4364dd9a0ef3;
0x7c3db723f1d4d8cb9c550095203b686cb11e5c6b;
0xe7387473b067235436884d16799777cf279edf65.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Goldman Sachs comments on AMD (AMD.US) Q3 performance: Data center CPU and GPU show strong performance, growth visibility for 2027 is clear
Goldman Sachs released a research report maintaining a "Buy" rating on AMD (AMD.US) with a 12-month target price of $675.

A recorder hidden in toilet paper exposes OpenAI's long-standing safety issues

AbbVie (ABBV.US) expands Oxford R&D facility in UK, betting on innovation in immunology, neuroscience, and oncology drugs
AbbVie announced on Wednesday that, as part of an investment plan exceeding 120 million pounds (approximately $161 million), the company has expanded its research and development facility in Oxford, United Kingdom.
